Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20020093.Her2HRneg

— · E

3e779569-ab4f-5a38-8cee-4f0c6b3512fe

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
E
subtype
E

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.620
  • MYC_TARGETS_V1+0.580
  • MYC_TARGETS_V2+0.580
  • G2M_CHECKPOINT+0.530
  • INTERFERON_ALPHA_RESPONSE+0.440
  • UNFOLDED_PROTEIN_RESPONSE+0.370
  • INTERFERON_GAMMA_RESPONSE+0.330
  • MTORC1_SIGNALING+0.330
  • OXIDATIVE_PHOSPHORYLATION+0.330
  • SPERMATOGENESIS+0.300

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
  • UV_RESPONSE_DN-0.400
  • ANGIOGENESIS-0.370
  • MYOGENESIS-0.280
  • TNFA_SIGNALING_VIA_NFKB-0.260
  • TGF_BETA_SIGNALING-0.230
  • APICAL_JUNCTION-0.220
  • COAGULATION-0.220
  • NOTCH_SIGNALING-0.220
  • ANDROGEN_RESPONSE-0.210

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518323
breast-umap@18
—E0.902
2SRR8518289
breast-umap@18
—E0.891
3SRR8518168
breast-umap@18
—E0.888
4TCGA-A2-A4S3-01A-21R-A266-07
breast-umap@18
—B0.884
5TCGA-58-A46M-01A-11R-A24H-07
lung-landscapes@6
—cohortSQ20.883
6SRR8613729
breast-umap@18
—E0.872
7s0112318
melanoma-umap@29
——0.870
8SRR6013511
lung-landscapes@6
—cohortSQ10.870
9BS_MMNRZ1EQ
brain-umap@2
ATRT—0.869
10SRR8518360
breast-umap@18
—E0.869

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.620Inavolisib— uncovered
MYC_TARGETS_V10.580Inavolisib— uncovered
MYC_TARGETS_V20.580Idelalisib— uncovered
G2M_CHECKPOINT0.530Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.440Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.370Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.330Idelalisib— uncovered
MTORC1_SIGNALING0.330Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.330Remibrutinib— uncovered
SPERMATOGENESIS0.300Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.250Inavolisib— uncovered
DNA_REPAIR0.220Idelalisib— uncovered
MITOTIC_SPINDLE0.220Inavolisib— uncovered
ALLOGRAFT_REJECTION0.200Idelalisib— uncovered
GLYCOLYSIS0.150Inavolisib— uncovered
UV_RESPONSE_UP0.110Idelalisib— uncovered
APICAL_SURFACE0.060Temsirolimus— uncovered
ADIPOGENESIS0.050Inavolisib— uncovered
PANCREAS_BETA_CELLS0.050Cobimetinib— uncovered